Compare AstraZeneca plc (AZN) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Bitcoin Trust — how do they compare? AstraZeneca plc trades at $158.11 (market cap $250.84B), while iShares Bitcoin Trust trades at $36.1. The key difference: AstraZeneca plc pays a 1.97% dividend while iShares Bitcoin Trust pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| AZN | IBIT | |
|---|---|---|
Market Cap | $250.84B | — |
Sector | Health | Crypto-linked |
52-Week High | $209.48 | $71.29 |
52-Week Low | $147.06 | $33.29 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
IBIT trades at $36.80, up 0.85% today, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $36 and resistance at $37. Recent news highlights strong institutional interest, with BlackRock's head of digital assets noting 'overwhelming demand' for crypto ETFs (Bloomberg, 2026-08-10).
The outlook is cautiously optimistic given technical strength and institutional inflows, but risks include Bitcoin price volatility and regulatory uncertainty. Analyst sentiment is mixed, with some recommending long-term buys amid crypto market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
